Follow–up beyond 1 month after autologous CAR T cell therapy

Authors

  • Andreza Alice Feitosa Ribeiro

DOI:

https://doi.org/10.46765/2675-374X.2022v3n2p181

Abstract

The incidence of medium-term and long-term adverse events are critical factors determining the utility of CAR T-cell therapy and research of risk factors and timeline of late effects will be critical for optimal survivorship care. The most commonly reported toxicities during long-term follow-up after anti-CD19 CAR T-cell therapy are decreased blood B-cell counts, hypogammaglobulinemia, prolonged cytopenias and infections. Common determinants of late toxicities are age, underlying tumor type, previous therapy and CAR construct. Here we will provide some recommendations for patient monitoring during medium-term and long-term follow-up and management of the late adverse effects.

Downloads

Published

11/23/2022

How to Cite

Ribeiro, A. A. F. (2022). Follow–up beyond 1 month after autologous CAR T cell therapy. JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY, 3(2), 181. https://doi.org/10.46765/2675-374X.2022v3n2p181

Issue

Vol. 3 No. 2 (2022): Journal of Bone Marrow Transplantation and Cellular Therapy

Section

Original article

License

Copyright (c) 2022 JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

License and Copyright Policy

The Journal of Bone Marrow Transplantation and Cellular Therapy (JBMTCT) adopts an open access policy, ensuring that all published articles are freely available to the public without restrictions.

  1. License

    • All articles published in JBMTCT are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0).
    • This license permits anyone to:
      • Share: Copy and redistribute the material in any medium or format.
      • Adapt: Remix, transform, and build upon the material for any purpose, even commercially.
    • The only requirement is that appropriate credit is given to the original authors and source, a link to the license is provided, and any changes made are indicated.

    More information about the license can be found here: Creative Commons Attribution 4.0 International License.

  2. Authors’ Rights

    • Authors retain the copyright to their work.
    • Authors grant JBMTCT the right to publish the work and make it openly accessible online.
    • Authors are free to:
      • Distribute the published version of their article (e.g., post it on personal websites or institutional repositories).
      • Use the article in future works, presentations, or derivative publications, as long as the original publication in JBMTCT is properly acknowledged.

  3. No Embargo

    • There is no embargo period; articles are made freely available immediately upon publication.

  4. Ethical Use

    • Users of JBMTCT articles must ensure proper citation of the authors and the journal.
    • Articles must not be used in ways that violate ethical or legal standards.

  5. Disclaimer

    • While JBMTCT aims to ensure the accuracy and reliability of published content, the journal and its editors are not responsible for the consequences of its use.

For any questions regarding our licensing terms, please contact us at: journalbmtct@sbtmo.org.br 

JBMTCT is committed to the principles of open access to advance knowledge and scientific collaboration.

 

Most read articles by the same author(s)